Data for: A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study

Published: 09-01-2019| Version 1 | DOI: 10.17632/ffg8fv5ph5.1
Contributors:
Antonio Llombart,
Antonio Antón,
Isabel Garau,
Mirta García,
José Juan Illarramendi,
Cesar Rodriguez,
Noemia Afonso,
Elena Aguirre,
Pilar Zamora,
Miguel Sampayo,
Vanesa Ortega,
Esperanza Blanco,
María Martínez-García,
Javier Cortes,
Lourdes Calvo,
Jose Perez Garcia,
Yolanda Fernández

Description

A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study

Files